Hannah Clarke

"I think NAI plus BCG will be a game-changer in the community, probably more than it would be in academic medical settings," says Karim Chamie, MD.

“The number of views, viewer engagement, and the length of the video didn't have an impact on the score at all when we did our analysis,” says Daniel Bockelman.

As the year comes to a close, we revisit some of this year’s top content on malpractice in urology.

As the year comes to a close, we revisit some of this year’s top content on urologic stones.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging.

Dr. Butler discusses 2022 milestones from her practice in gender-affirming care and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on coding and reimbursement for urologic procedures.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

Thomas Chi, MD, discusses 2022 milestones in stone disease and looks ahead to what might be on the horizon for the field in the coming year.

Investigators found that mitigation methods such as adding a physical barrier or increasing distance could lessen the harmful effects.

As the year comes to a close, we revisit some of this year’s top content on diversity, equity, and inclusion.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"The previous group who had looked at this saw a 15% adherence to the AUA guidelines up to 2013. We're doing better, but not much better," says Megan Prunty, MD.

“Even though we set some priority areas, we also allow practicing urologists to make suggestions for things that they want to know about,” says Amanda North, MD.

Dr. Van Kuiken discusses 2022 milestones in FPMRS and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

“The bottom line is that [gender parity] starts with sponsorship and bringing women to the table in academic leadership positions so that our voices can be heard,” says Bridget Lang Findlay, MD.

"I am prepared and excited to be fully immersed in the health policy work of the AUA as the 2023 Gallagher Scholar," says Denise Asafu-Adjei, MD, MPH.

The clinical research program seeks to increase the number of URiM medical students entering the field of urology.

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

Amanda North, MD, discusses the AUA census in depth, specifically highlighting the data collected on residents and fellows.

The study found pathogenic or likely pathogenic variants in DNA damage repair genes and HOXB13 to be more frequently observed in Black men with a family history of cancer.

The median DOR among the 15 patients in the study was 24.4 months (range, 10.1 to 30.7 months).

"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.

Risk of tumor recurrence in the BLC Registry group was significantly lower than in patients who received WLC alone.

The collaboration between Streamline Scientific and UroGPO will help deliver PCR technology to UroGPO members.

“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.

The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.

“I think a clinical trial like this that is funded by the NIH and taxpayer dollars will hopefully provide an unbiased answer of whether it works and who it works in,” says Ranjith Ramasamy, MD.